BioGenerator Ventures is an early-stage investor in St. Louis-based life science companies. As of 2025, we have invested in over 130 companies across the human health and agriculture technology sectors. We are often the first professional capital into portfolio companies, and we actively syndicate deals with capital sources across the globe.
Detecting gene fusions with a patented ddPCR approach.
Status: Active
First Investment Year: 2024
Next-generation metabolomics® and proteomics with integrated multi-omic data analysis.
Status: Active
First Investment Year: 2022
Using gene editing to develop a novel sterile insect technology approach for pest control.
Status: Active
First Investment Year: 2022
Accelerates agricultural innovation through specialized research services like plant transformation, gene editing, and consulting.
Status: Active
First Investment Year: 2021
RNA detection platform to screen for colorectal cancer and other GI diseases.
Status: Active
First Investment Year: 2021
Virtual care and remote patient monitoring platform for diabetes care providers.
Status: Active
First Investment Year: 2020
Expanding the range of bioconjugate vaccines to fight more bacterial threats.
Status: Active
First Investment Year: 2019
Developing off-the-shelf cellular therapies for cancer.
Status: Active
First Investment Year: 2018
Enhancing the performance of Bt biopesticides for safer, more effective, and sustainable insect control solutions.
Status: Active
First Investment Year: 2018
Harnessing chloroplasts in plant cells to deliver traits that enhance crop yields, resistance, and efficiency.
Status: Active
First Investment Year: 2017
AR technology to provide physicians with a 360-degree view of the treatment they’re delivering.
Status: Active
First Investment Year: 2017
Developing fluorescent tracer agents and transdermal detection technology for physiological monitoring.
Status: Active
First Investment Year: 2012
Proprietary blood pump system to increase eligibility and improve outcomes for arteriovenous fistula surgery.
Status: Active
First Investment Year: 2025
Novel molecular approach for precise trait insertion in plant genomes.
Status: Active
First Investment Year: 2025
Using artificial intelligence to predict breast cancer risk and inform treatment paths.
Status: Active
First Investment Year: 2025
Small molecule therapeutics for the treatment of obesity.
Status: Active
First Investment Year: 2024
Disposable, transcutaneous auricular vagus nerve stimulator to reduce complications in the ICU.
Status: Active
First Investment Year: 2024
Utilizes a bio-molecular platform based on Triacetic Acid Lactone (TAL) to produce novel and safe pesticides.
Status: Active
First Investment Year: 2024
Designs and manufactures eco-friendly, high-performance materials made from plant-based fibers for architecture and automotive industries.
Status: Active
First Investment Year: 2024
Improving grip ability by blocking hyperhydrosis.
Status: Active
First Investment Year: 2023
Helping providers do their jobs more effectively and efficiently.
Status: Active
First Investment Year: 2023
Developing a novel vaccine against staphylococcus aureus.
Status: Active
First Investment Year: 2023
Developing computational tools to improve cell differentiation and iPSC engineering.
Status: Active
First Investment Year: 2023
Multi-modal thrombectomy device for the treatment of deep vein thrombosis.
Status: Active
First Investment Year: 2023
Developing small electromagnetic sensors for force sensing applications.
Status: Active
First Investment Year: 2023
Empowering renewable energy through oil extraction to revitalize corn demand.
Status: Active
First Investment Year: 2023
Provides technologies and services for breeding genomics.
Status: Exit
First Investment Year: 2023
Provides formulation services to transform novel ingredients into stable and effective products for agriculture.
Status: Active
First Investment Year: 2023
Developing industrial hemp as a competitive grain crop alternative for oil, food, and feed.
Status: Active
First Investment Year: 2023
Bringing a portfolio of health-benefitting traits in fruits & vegetables, starting with the Purple Tomato™.
Status: Active
First Investment Year: 2023
Helps agribusinesses execute seamless field trials and data analysis for the trusted results needed to drive product success.
Status: Active
First Investment Year: 2023
Mechanism of action technologies (MOAT) platform for drug target identification and development.
Status: Active
First Investment Year: 2023
Creating "sensible instruments" for use in scientific analyses.
Status: Active
First Investment Year: 2022
Immune checkpoint blockade therapy response prediction.
Status: Active
First Investment Year: 2022
Tissue retentive formulations for safer, more effective cancer immunotherapy treatments.
Status: Active
First Investment Year: 2022
Establishing a discovery platform for designing new proteins for a wide range of applications; the first product is a bio-fungicide.
Status: Active
First Investment Year: 2022
Creates a customizable, crop-plot environmental sensor and phenotyping station for real-time measurements of environmental conditions.
Status: Active
First Investment Year: 2022
Discovering and designing novel anti-microbial peptides as alternatives to chemical fungicides.
Status: Exit
First Investment Year: 2022
Creating an innovative method for regulating gene expression to produce crops with improved traits.
Status: Active
First Investment Year: 2022
Developing a small molecule inhibitor of ACSS2 for the treatment of TNBC and NSCLC.
Status: Active
First Investment Year: 2021
Sepsis patient prognostication and segmentation through immunophenotyping.
Status: Active
First Investment Year: 2021
Developing a transcatheter system to safely excise tissue and treat heart failure patients.
Status: Active
First Investment Year: 2021
Advancing vaccine technology to solve challenging swine diseases.
Status: Active
First Investment Year: 2021
Developing first-in-class non-absorbed oral therapeutics to prevent and treat iron-related diseases.
Status: Active
First Investment Year: 2021
Unleashing the power of liquid biopsy to detect and fight cancer.
Status: Active
First Investment Year: 2021
Enabling therapy access to undiagnosed sleep apnea patients with the first rapid, awake diagnostic.
Status: Active
First Investment Year: 2020
A novel system for delivery of cargo to difficult to transfect cell types.
Status: Active
First Investment Year: 2020
Developing a test to monitor disease progression in cancer patients via cfDNA
Status: Active
First Investment Year: 2020
Advancing therapeutic treatments for liver diseases and heart failure.
Status: Active
First Investment Year: 2020
Curating, enhancing, and transforming real-world, de-identified health data to help researchers solve clinical challenges.
Status: Exit
First Investment Year: 2020
Developing advanced adenoviral vaccines.
Status: Active
First Investment Year: 2020
Developing anti-VEGFR-3 monoclonal antibodies for the treatment of cancer.
Status: Active
First Investment Year: 2020
Offering fast and convenient high-protein waffle sandwiches.
Status: Active
First Investment Year: 2019
Accelerating the development of multiple early-stage therapeutic assets.
Status: Active
First Investment Year: 2019
Provides cloud-based, digital solutions for companies in the agriculture & animal health industries.
Status: Active
First Investment Year: 2019
Developing a dried, bio-inspired artificial red blood cell to treat life-threatening blood loss.
Status: Active
First Investment Year: 2018
Developing a small molecule, oral therapy to treat primary hyperoxaluria, a rare orphan metabolic disease.
Status: Active
First Investment Year: 2018
Addresses key challenges related to equipment, machinery, and the environment using wireless IoT sensors.
Status: Active
First Investment Year: 2017
Cloud-based EHR for long-term post-acute care providers.
Status: Exit
First Investment Year: 2017
Empowering care teams, patients and family to overcome the inherent challenges of care coordination.
Status: Active
First Investment Year: 2016
Establishing a more sustainable and domestic source of natural rubber using sunflowers.
Status: Active
First Investment Year: 2016
Harnessing patient data and AI-driven technology to transform the discovery and development of life-changing medicines.
Status: Exit
First Investment Year: 2016
Providing access to cutting-edge spatial biology and multi-omic tools so researchers can drive scientific discovery.
Status: Exit
First Investment Year: 2016
Developing an external wearable device to aid in low calorie diet compliance.
Status: Active
First Investment Year: 2015
Surgical retina instrumentation.
Status: Exit
First Investment Year: 2015
Remote patient monitoring for value-based organizations.
Status: Exit
First Investment Year: 2015
Predictive diagnostics to match cancer patients to immunotherapy treatment.
Status: Active
First Investment Year: 2015
Utilizing a novel drug-targeting technology for cancer therapy.
Status: Active
First Investment Year: 2015
Developing virus immunotherapy products to treat cancer.
Status: Active
First Investment Year: 2015
Developing novel tests for prostate cancer.
Status: Active
First Investment Year: 2014
Developing small molecule compounds for the treatment of CNS disorders including chronic pain and addiction.
Status: Active
First Investment Year: 2014
Medical devices for obesity and type 2 diabetes.
Status: Exit
First Investment Year: 2014
Pioneering the field of interventional immuno-oncology through novel treatments for solid-tumor cancers.
Status: Active
First Investment Year: 2014
Developing serum tests that will distinguish aggressive from indolent cancers.
Status: Active
First Investment Year: 2013
Specializing in electrosurgery, surgical site illumination and microsurgical instrumentation.
Status: Exit
First Investment Year: 2013
Detecting UTIs directly from urine samples.
Status: Active
First Investment Year: 2013
Unlocking nature’s genetic diversity in soy quality traits.
Status: Exit
First Investment Year: 2013
Enabling easier access to regulatory information with a novel regulatory intelligence system.
Status: Active
First Investment Year: 2012
Establishing and performing novel safety pharmacology assays to evaluate the safety of therapeutics on ion channel function in heart tissue.
Status: Exit
First Investment Year: 2011
Specializes in RNAi-based biopesticides for sustainable pest management.
Status: Active
First Investment Year: 2011
Delivers real-time information on highly-labile cytokines to bring faster, more precise clinical decisions within reach.
Status: Active
First Investment Year: 2011
Addressing two areas in the development of biologics: biosimilar drug comparability analysis and impurity analysis.
Status: Exit
First Investment Year: 2011
Manufacturing Active Pharmaceutical Intermediates for Class II-V controlled substances.
Status: Exit
First Investment Year: 2011
Ophthalmic perioperative pharmaceuticals.
Status: Exit
First Investment Year: 2011
Advancing the next generation of oral drugs that disrupt the tumor microenvironment and kill cancer cells.
Status: Active
First Investment Year: 2011
Providing unique medicinal chemistry services to advance drug discovery.
Status: Exit
First Investment Year: 2010
Treating blood clots in stroke patients with magnetic nanoparticles.
Status: Active
First Investment Year: 2010
Providing biochemistry, biomarker, target validation and other services to pharma and academic clients.
Status: Exit
First Investment Year: 2010
Using microbes to convert carbon dioxide to renewable methane, which replaces fossil fuels.
Status: Active
First Investment Year: 2010
Developing novel therapies that have the potential to improve the anti-cancer efficacy of treatments for breast cancer.
Status: Exit
First Investment Year: 2010
Improving motor recovery after a stroke with brain-computer interfaces.
Status: Active
First Investment Year: 2008
Transforming human apyrase into life-saving medicine.
Status: Exit
First Investment Year: 2006
“BioGenerator was deeply committed to working with the founders to build a successful company. Without the ongoing support of BioGenerator, the Confluence story would never have happened.”
“BioGenerator played a critical role in leading our initial financing - putting together the due diligence and orchestrating additional investors. Their commitment to supporting Benson Hill in multiple ways beyond their share of invested capital is part of the reason we are excited to call St. Louis home.”
“BioGenerator’s model has helped grow companies like Benson Hill into quality, highly-attractive investments for venture investors.”
“The network BioGenerator has is really invaluable and their active support from pre-company licensing through our Series A round was critical in getting the company to where it is today.”
“BioGenerator is a significant value-add investor, while also being a great source of life science deal flow. The quality of the investment opportunity combined with the professionalism they brought to due diligence and the deal process allowed us to move very quickly.”
“BioGenerator has been instrumental in launching our company—from learning how to be successful academic founders to the details of starting and financing SentiAR, our spin out from Washington University. They have made crucial introductions to industry leaders at appropriate times and invested in our company. We could not have embarked down this path without all the support from the BioGenerator team!”
“The St. Louis startup community is flourishing. We’ve discovered and invested in several of our most promising companies there. I continue to be impressed by the BioGenerator model and the quality of its portfolio.”
